Medtronic PLC vs Marqeta Inc — how do they compare? Medtronic PLC trades at $88.08 (market cap $112.24B), while Marqeta Inc trades at $17.87 (market cap $1.82B). The key difference: Medtronic PLC is far larger — about 61.7× Marqeta Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Marqeta Inc for 44 Days on average.
| MDT | MQ | |
|---|---|---|
Market Cap | $112.24B | $1.82B |
Volume | 105,663,236 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $105.35 | $20.32 |
52-Week Low | $73.75 | $15.04 |
Typical Hold Time | 63 Days | 44 Days |
Enterprise Value | $131.58B | $1.13B |
Dividend Yield | 3.28% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Marqeta (MQ) trades at $17.86, up 4.69% with a bullish technical outlook. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow generation in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives. However, valuation remains elevated with a P/E of 193.83 and EV/EBITDA of 54.37 despite modest profitability metrics.
MQ presents a mixed investment case with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and product innovation, though faces risks from contract renewals and competitive pressure. Analyst consensus at $11.38 suggests caution despite recent positive earnings revisions and institutional interest in the fintech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →